Accueil > The PARCC

The PARCC

The National Institute for Health and Medical Research (Inserm) and the University Paris Descartes opened the Paris-Cardiovascular research Center (PARCC) at the Georges-Pompidou European Hospital (HEGP) in 2009.
More than 250 scientists, students, technicians and administrative staff, who initially were housed in several locations in Paris, were brought together under one roof on a 4200 m² site.

The main mission of the PARCC is to establish an optimal scientific and medical environment in order to promote excellence in the development of and training in translational Cardiovascular Research.

The objective of the PARCC is to create a world-class environment for basic and translational research and training focused on cardiovascular diseases, which represent the highest socioeconomic burden of all diseases worldwide with major unmet medical needs. Inserm, University Paris Descartes and AP-HP are joining resources in partnership with the PARCC to establish the expertise and facilities needed to lead research “from bench to beside and back again”. A broad spectrum of cardiovascular research is covered, spanning basic molecular and cellular biology to integrated physiology and pathophysiology, biomarkers, genetics and epidemiology.
Translational research is an integral part of the mission of the Center, in direct continuity with the clinical laboratories and departments of the HEGP hospital. Translational research opportunities encompass work on etiology and pathogenesis, therapeutic intervention, and resolution and repair of clinically critical forms of cardiovascular disease, encountered in atherosclerosis, thrombosis, hypertension, diabetes mellitus, heart failure and sudden cardiac death.

The director :

Alain Tedgui obtained his PhD thesis in Fluid Mechanics. After his post-doctoral fellowship at the Imperial College, London, he joined the French Institute of Health and Medical Research (Inserm) in 1983. He has been heading an INSERM laboratory at Paris Hospital Lariboisière from 2000 to 2004. His is currently the Director of the PARCC (Paris-Cardiovascular research Center) at the Georges-Pompidou European Hospital. He coordinated the European Network of Excellence EVGN (European Vascular Genomics Network) from 2004 to 2008. His current primary research is aimed at elucidating the role of apoptosis and inflammation in atherosclerosis. More recently, he bridged the interface between vascular biology and immunology in showing that a subset of immune cells, regulatory T cells, limits the development of atherosclerosis and can be used as a promising anti-atherosclerotic strategy to curtail inflammation. He was the European Editor of Arteriosclerosis Thrombosis and Vascular Biology from 2008 to 2012.